Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 5, 2008, Pages 491-500

  Dasbach, Erik J ^a   Largeron, Nathalie ^b   Elbasha, Elamin H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Cost effectiveness analysis; Dynamic model; Genital warts; Human papillomavirus; Vaccine

Indexed keywords

WART VIRUS VACCINE;

AGE; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SCREENING; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DYNAMIC TRANSMISSION MODEL; HEALTH PROGRAM; INCIDENCE; MATHEMATICAL MODEL; NORWAY; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

EID: 68749094411     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.5.491     Document Type: Article

References (48)

1. Walboomers J, Jacobs M, Manos M et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12-19 (1999).
2. Baseman J, Koutsky L. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl. 1), S16-S24 (2005).
3. Jacobs M, de Roda Husman A, van den Brule A, Snijders P, Meijer C, Walboomers J. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J. Clin. Microbiol. 33(4), 901-905 (1995).
4. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121(3), 621-632 (2007).
5. Clifford G, Gallus S, Herrero R et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366(9490), 991-998 (2005).
6. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur. J. Dermatol. 11(6), 598-603 (2001).
7. Maw R, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. STD AIDS 9, 571-578 (1998).
8. Lacey C, Lowndes C, Shah K. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24(S3), 35-41 (2006).
9. Munoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 24(Suppl. 3), S1-S10 (2006).
10. Nygard J, Skare G, Thoresen S. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med. Screen. 9(2), 86-91 (2002).
11. Cancer Registry of Norway. Cancer in Norway 2006 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo. (2007).
12. Norwegian Institute of Public Health. Evaluation and recommendation for the use of the HPV vaccine. (2007).
13. Joura E, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet, 1693-1702 (2007).
14. European Medicines Agency (EMEA). Gardasil European Public Assessment Report (EPAR). 1-40 (2008).
15. Dasbach E, Elbasha E, Insinga. R. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev. 28(1), 88-100 (2006).
16. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int. J. Technol. Assess. Health Care 24, 10-19 (2008).
17. Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoSMed. 3(5), e138 (2006).
18. Kim J, Andres-Beck B, Goldie S. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br. J. Cancer 97, 1322-1328 (2007).
19. Goldhaber-Fiebert J, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J. Natl Cancer Inst. 100(5), 308-320 (2008).
20. Kulasingam S, Connelly L, Conway E. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex. Health, 165-175 (2007).
21. Kulasingarn SL, Benard S, Barnabas R, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff. Resour. Alloc. 6, 4 (2008).
22. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 (29), 5399-5408 (2007).
23. Elbasha E, Dasbach E, Insinga R. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 13(1), 28-41 (2007).
24. French K, Barnabas R, Lehtinen M et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br. J. Cancer 96(3), 514-518 (2007).
25. Regan D, Philp D, Hocking J, Law M. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex. Health 4 (3), 147-163 (2007).
26. Günther O, Ogilvie G, Naus M et al. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity? J. Infect. Dis. 197(12), 1653-1661 (2008).
27. Kim J, Goldie S. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359 (8), 821-832 (2008).
28. Neilson A. Freislebel de Blasio. Økonomisk evaluering av humant papillomavirus (HPV)-vaksinasjon i Norge. Rapport Nr 12-2007. Oslo. Nasjonalt kunnkapssenter for hesetjenesten, (2007).
29. Dasbach E, Insinga R, Elbasha E. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the United Kingdom. BJOG (2008).
30. Insinga R, Dasbach E, Elbasha E, Puig A, Reynales-Shigematsu L. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26(1), 128-139 (2007).
31. Bjorge T, Gunbjorud A, Haugen O, Skare G, Trope C, Thoresen S. Mass screening for cervical cancer in Norway: evaluation of the pilot project. Cancer Causes Control6(6), 477-484 (1995).
32. Chesson H, Ekwueme D, Saraiya M, Markowitz L. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerz. Infect. Dis. 14(2), 244-251 (2008).
33. The Directorate for Health and Social Affairs. Activity Based Financing. (2003).
34. The Norwegian Medical Association. Fee schedule for private practicing specialists. (2003).
35. Ministry of Health and Care. Fee schedule for outpatient care. (2003).
36. Insinga R, Dasbach E, Myers E. The health and economic burden of genital warts in a set of private health plans in the United States. Clin. Infect, Dis. 36(11), 1397-1403 (2003).
37. Norwegian Institute of Public Health. National Survey of Sexuality and Health. (2002).
38. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisals. (2004).
39. The Norwegian Medicines Control Authority. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. (2000).
40. Evans C. Use of Quality adjusted life years and life year gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag. Sci. 7, 43-49 (2004).
41. Norwegian Directorate of Health. Social-og helsedirektoratet. Helseeffekter i samfunnsøkonomiske analyser. Order-number IS-1435. (2007).
42. Barnabas R, Kulasingam S. Economic evaluations of human papillomavirus vaccines. Expert Rev. Pharmacoeconomics Outcomes Res. 7(3), 251-267 (2007).
43. Edmunds W, Medley G, Nokes D. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18, 3263-3282 (1999).
44. Villa L. Quadrivalent human papillomavirus, (HPV) types 6/11/16118 Ll virus-like particle vaccine: first analysis of cross-protection against cervical intraepithelial neoplasia. (CIN) and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. EUROGIN, 1-1 (2007).
45. Carter J, Madeleine M, Shera K et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 61(5), 1934-1940 (2001).
46. Hobbs C, Sterne J, Bailey M, Heyderman R, Birchall M, Thomas S. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin. Otolaryngol. 31(4), 259-266 (2006).
47. Freed G, Derkay C. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int. J Pediatr. Otorhinolaryngol. 70(10), 1799-1803 (2006).
48. Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin. Infect. Dis. 45, 609-617 (2008).